CN110072536B - 丝状病毒共有抗原、核酸构建体和由其制成的疫苗及其使用方法 - Google Patents

丝状病毒共有抗原、核酸构建体和由其制成的疫苗及其使用方法 Download PDF

Info

Publication number
CN110072536B
CN110072536B CN201780042299.9A CN201780042299A CN110072536B CN 110072536 B CN110072536 B CN 110072536B CN 201780042299 A CN201780042299 A CN 201780042299A CN 110072536 B CN110072536 B CN 110072536B
Authority
CN
China
Prior art keywords
seq
thr
consensus
leu
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780042299.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN110072536A (zh
Inventor
大卫·B·韦纳
阿米·帕特尔
严健
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania
The Wistar Institute
Inovio Pharmaceuticals Inc
Original Assignee
University of Pennsylvania
The Wistar Institute
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania, The Wistar Institute, Inovio Pharmaceuticals Inc filed Critical University of Pennsylvania
Priority to CN202410055051.8A priority Critical patent/CN117887735A/zh
Publication of CN110072536A publication Critical patent/CN110072536A/zh
Application granted granted Critical
Publication of CN110072536B publication Critical patent/CN110072536B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201780042299.9A 2016-05-05 2017-05-05 丝状病毒共有抗原、核酸构建体和由其制成的疫苗及其使用方法 Active CN110072536B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410055051.8A CN117887735A (zh) 2016-05-05 2017-05-05 丝状病毒共有抗原、核酸构建体和由其制成的疫苗及其使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662332372P 2016-05-05 2016-05-05
US62/332,372 2016-05-05
US201662402519P 2016-09-30 2016-09-30
US62/402,519 2016-09-30
US201762483979P 2017-04-11 2017-04-11
US62/483,979 2017-04-11
PCT/US2017/031215 WO2017192947A1 (en) 2016-05-05 2017-05-05 Filovirus consensus antigens, nucleic acid constructs and vacciens made therefrom, and methods of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410055051.8A Division CN117887735A (zh) 2016-05-05 2017-05-05 丝状病毒共有抗原、核酸构建体和由其制成的疫苗及其使用方法

Publications (2)

Publication Number Publication Date
CN110072536A CN110072536A (zh) 2019-07-30
CN110072536B true CN110072536B (zh) 2024-02-02

Family

ID=60203604

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780042299.9A Active CN110072536B (zh) 2016-05-05 2017-05-05 丝状病毒共有抗原、核酸构建体和由其制成的疫苗及其使用方法
CN202410055051.8A Pending CN117887735A (zh) 2016-05-05 2017-05-05 丝状病毒共有抗原、核酸构建体和由其制成的疫苗及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410055051.8A Pending CN117887735A (zh) 2016-05-05 2017-05-05 丝状病毒共有抗原、核酸构建体和由其制成的疫苗及其使用方法

Country Status (11)

Country Link
US (3) US11091518B2 (enExample)
EP (1) EP3452068A4 (enExample)
JP (3) JP7029756B2 (enExample)
KR (2) KR102678400B1 (enExample)
CN (2) CN110072536B (enExample)
AU (2) AU2017261306B2 (enExample)
BR (1) BR112018072719A2 (enExample)
CA (1) CA3023098A1 (enExample)
MX (2) MX2018013524A (enExample)
SG (2) SG11201809780WA (enExample)
WO (1) WO2017192947A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102678400B1 (ko) * 2016-05-05 2024-06-26 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 필로바이러스 공통 항원, 이로부터 제조된 핵산 구조체 및 백신, 및 이를 사용하는 방법
WO2018102657A1 (en) * 2016-12-02 2018-06-07 Weiner David B Dna antibody constructs for use against ebola virus
CN110655572B (zh) * 2019-10-11 2022-08-16 中国科学院广州生物医药与健康研究院 一种抗丝状病毒gp蛋白的单克隆抗体及其应用
WO2024233996A2 (en) * 2023-05-11 2024-11-14 The Wistar Institute Of Anatomy And Biology Vaccines against african swine fever virus, and methods of using same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104884083A (zh) * 2012-04-12 2015-09-02 宾夕法尼亚大学理事会 丝状病毒共有抗原、由其制备的核酸构建体和疫苗以及其使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8298820B2 (en) * 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
WO2014145951A2 (en) * 2013-03-15 2014-09-18 The Trustees Of The University Of Pennsylvania Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
SG10201806481XA (en) * 2014-02-19 2018-09-27 Emergent Biosolutions Canada Inc Marburg monoclonal antibodies
AU2015311852B2 (en) * 2014-09-03 2018-12-13 Bavarian Nordic A/S Methods and compositions for inducing protective immunity against filovirus infection
KR102586707B1 (ko) * 2014-10-01 2023-10-11 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 항원 및 어쥬번트로서 인터류킨-21을 갖는 백신
KR102678400B1 (ko) * 2016-05-05 2024-06-26 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 필로바이러스 공통 항원, 이로부터 제조된 핵산 구조체 및 백신, 및 이를 사용하는 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104884083A (zh) * 2012-04-12 2015-09-02 宾夕法尼亚大学理事会 丝状病毒共有抗原、由其制备的核酸构建体和疫苗以及其使用方法

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
A Single Immunization With Optimized DNA Vaccines Protects Against Lethal Ebola Virus Challenge in Mice and Induces Seroconversion in Non-Human Primates Following a DNA Prime–DNA Boost Approach;Ami Patel等;《Molecular Therapy》;20150531;第23卷;第S178-S179，450 *
GP1,2 [Zaire ebolavirus], Accession No. AIW47454.1;Hoenen,T.;《Genebank数据库》;20150130;第1页"ORIGIN" *
Hoenen,T.等.Zaire ebolavirus isolate H.sapiens-tc/GIN/14/WPG-C05, complete genome, Accession No. KP096420.1.《Genebank数据库》.2015,第2页/product="GP1,2"、第3-6页"ORIGIN". *
Isolates of Zaire ebolavirus from wild apes reveal genetic lineage and recombinants;Tatiana J. Wittmann等;《Proceedings of the National Academy of Sciences of the United States of America》;20071023;第104卷(第43期);全文 *
virion spike glycoprotein precursor [Zaire ebolavirus], Accession No. AGB56830.1;Carroll,S.A.;《Genebank数据库》;20140912;第1页"ORIGIN" *
Zaire ebolavirus isolate H.sapiens-tc/GIN/14/WPG-C05, complete genome, Accession No. KP096420.1;Hoenen,T.等;《Genebank数据库》;第2页/product="GP1,2"、第3-6页"ORIGIN" *
埃博拉病毒疫苗研究进展;黄德东等;《现代免疫学》;20150930;第35卷(第5期);全文 *
王学林等.《分子药理学》.中国医药科技出版社,2011,第302-303页"十一、埃博拉病毒疫苗". *

Also Published As

Publication number Publication date
CN117887735A (zh) 2024-04-16
AU2017261306A1 (en) 2018-12-20
SG10202011017RA (en) 2020-12-30
AU2017261306B2 (en) 2024-02-29
JP2022078067A (ja) 2022-05-24
WO2017192947A1 (en) 2017-11-09
MX2018013524A (es) 2019-06-10
EP3452068A1 (en) 2019-03-13
CA3023098A1 (en) 2017-11-09
JP7584770B2 (ja) 2024-11-18
US12240872B2 (en) 2025-03-04
JP2025017370A (ja) 2025-02-05
KR20190037200A (ko) 2019-04-05
JP2019516400A (ja) 2019-06-20
BR112018072719A2 (pt) 2019-02-19
SG11201809780WA (en) 2018-12-28
US20190153040A1 (en) 2019-05-23
KR20240099514A (ko) 2024-06-28
US20210388033A1 (en) 2021-12-16
AU2024203524A1 (en) 2024-06-20
CN110072536A (zh) 2019-07-30
KR102678400B1 (ko) 2024-06-26
MX2023003934A (es) 2023-04-26
US11091518B2 (en) 2021-08-17
JP7029756B2 (ja) 2022-03-04
EP3452068A4 (en) 2020-01-22
US20250257101A1 (en) 2025-08-14

Similar Documents

Publication Publication Date Title
US20240100143A1 (en) Filovirus Consensus Antigens, Nucleic Acid Constructs And Vaccines Made Therefrom, And Methods Of Using Same
AU2024203524A1 (en) Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
HK40011840B (en) Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
HK40011840A (en) Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
EA045714B1 (ru) Консенсусные антигены филовируса, конструкции нуклеиновых кислот и вакцины, полученные на их основе, и способы их применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40011840

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant